Loading
companiesCompany
Qilu Pharmaceutical
Qilu Pharmaceutical is a China-based pharmaceutical company running 20 late-stage cancer trials of QL1706, QLC5508 and QL2107 in non-small-cell lung cancer, oesophageal cancer and triple-negative breast cancer.
Also called: Qilu Pharmaceutical Co., Ltd.
Overview
Qilu Pharmaceutical, based in Jinan, China, is a pharmaceutical company. Qilu Pharmaceutical is a large Chinese pharmaceutical manufacturer that develops and produces innovative drugs, biosimilars, improved new drugs and generic medicines across oncology, cardiovascular, anti-infection and ophthalmology, among other areas. On ClinicalTrials.gov it is the lead sponsor of 20 recruiting or active phase 2 and phase 3 interventional cancer trials (13 in phase 3), testing QL1706, QLC5508, QL2107, QL0911 and ESG401 in non-small-cell lung cancer, oesophageal cancer, triple-negative breast cancer, multiple myeloma and HR-positive / HER2-negative breast cancer. The largest, NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), plans to enrol 808 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Jinan, CN
Scorecard
All companies#37of 1244 companies, score 82
- approved products +12
- phase 3 +18
- phase 1/2 +1
- targets +10
- modalities +10
- regions +1
- registry trials +30
2 approved, 6 in phase 3, 1 earlier, 5 targets, 360 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Phase 3ADC
QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
Phase 3bifunctional antibody mixture (iparomlimab and tuvonralimab; INN stem -mab)
QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
QLS32015 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
QLS31905 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
Phase 2protein degrader
QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.
ApprovedOral ALK and ROS1 tyrosine kinase inhibitor
Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.
ApprovedBifunctional antibody mixture: anti-PD-1 and anti-CTLA-4
QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.
cancers
drugs
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
ApprovedBifunctional antibody mixture: anti-PD-1 and anti-CTLA-4
ApprovedOral ALK and ROS1 tyrosine kinase inhibitor
Phase 3bifunctional antibody mixture (iparomlimab and tuvonralimab; INN stem -mab)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3ADC
Phase 2protein degrader
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
trials
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-LineA Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerA Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast CancerA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast CancerA Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage SmA Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaA Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerA Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon CancerA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical ResectionA Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancera Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After ChemoradiotherapyA Study of QLC5508 Combinations in Patients With Advanced Solid TumorsA Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsA Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic CancerA Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCCombination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast CancerPharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer PatientsPhase II Study of QLC2519 in Pediatric Solid Tumor ParticipantsPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple MyelomaPHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCQL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal CancerQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaQLS5132 Combination Therapy in Advanced Solid TumorsStudy Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStudy of MHB088C for Patients With Advanced Solid Malignant Tumors